MMMasoud Hassanzadeh Makoui

Masoud Hassanzadeh Makoui

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Masoud Hassanzadeh Makoui has a total of 34 co-authors. Here are the top co-authors by number of shared publications:

  • N. El Ansari

    Department of Internal Medicine, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran

    4 shared publications
  • Shiva Fekri

    Department of Gynecology and Obstetrics, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran

    4 shared publications
  • Mohammad Bahrami

    Student Research Committee, Department of Immunology, School of Medicine, Zanjan University of Medical Sciences

    2 shared publications
  • Negar Ansari

    Department of Internal Medicine, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran

    2 shared publications
  • Reza Hassanzadeh Makoui

    Department of Cardiology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran

    2 shared publications
  • Shiva Fekri

    Department of Gynecology and Obstetrics, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran

    2 shared publications

Latest Publications

  • Claudin 18.2: from a tight junction protein to a breakthrough target in solid tumor immunotherapy

    by Mohammad Bahrami, Masoud Hassanzadeh Makoui, Amir Bayat Bodaghi, Mansour Rajabi Vahid

  • Effect of Pentoxifylline on Inflammatory Markers in COVID-19: A Meta-Analysis of Randomized Controlled Trials

    by Danyal Imani, Navid Dashti, Amir Peymani, Ali Soltani, Masoud Hassanzadeh Makoui

    The hyperinflammatory response in COVID-19 is a major factor contributing to morbidity. Pentoxifylline, a methylxanthine derivative, has immunomodulatory properties, but its effects on inflammatory markers in COVID-19 remain unclear. This meta-analysis aims to evaluate the efficacy of pentoxifylline supplementation on CRP and interleukin-6 (IL-6) levels in these patients. A systematic search was conducted across multiple databases for randomized controlled trials (RCTs) published up to September 2025. Four RCTs, including 178 cases and 321 controls for CRP, and two RCTs, including 70 cases and 70 controls for IL-6, were included. Two reviewers independently performed data extraction and assessed the risk of bias using the Cochrane tool. Pooled standardized mean differences (SMDs) were calculated using a random-effects model. Heterogeneity was analyzed through meta-regression, and the conclusiveness of the evidence was evaluated using Trial Sequential Analysis (TSA). Pentoxifylline did not significantly reduce C-reactive protein (CRP) levels compared to the control group (SMD = −0.89; 95% CI: −1.85 to 0.07; p = 0.07). However, substantial heterogeneity was noted across the studies ( I 2 = 95.3%). Similarly, a nonsignificant trend toward reduction was observed for IL-6 (SMD = −0.22; 95% CI: −0.96 to 0.52; p = 0.55), accompanied by significant heterogeneity ( I 2 = 79.1%). Given the limited number of studies included, the results are inherently fragile, and one additional trial could substantially shift the pooled estimate. Meta-regression analysis indicated that patient age and publication year did not account for the heterogeneity, although there was a nonsignificant trend suggesting that a longer treatment duration might be associated with greater CRP reduction. TSA for CRP showed that cumulative evidence suggested futility and a lack of meaningful effect, confirming a significant lack of effect. The included studies generally had a low risk of attrition and reporting bias. Current evidence does not support the use of pentoxifylline for significantly reducing CRP or IL-6 levels in COVID-19 patients. The findings regarding CRP are considered conclusive, but the limited number of studies suggests that further trials on this outcome may alter this conclusion.

  • Open Access

    Common Statistical Challenges in Cytokine Studies

    by Mohammad Bahrami, Firouz Amani, Masoud Hassanzadeh Makoui

    Cytokines are among the most important regulators of immune responses and are widely used as biomarkers in both clinical and experimental immunology studies. Advances in multiplex measurement techniques have enabled the simultaneous assessment of multiple cytokines; however, the statistical analysis and interpretation of these data remain challenging. This letter provides ...

  • Graded transthoracic echocardiography findings and ischemic stroke characteristics in older adults: A cross-sectional stratified analysis

    by Mehdi Maghbooli, Samin Golabi Salmasi, Reza Hasanzadeh Makoui, Yasamin Josghasemi, Seyed Nariman Tavakoli Sany

  • Open Access

    Effect of HER3 Overexpression on Survival Outcomes in Pancreatic Cancer Patients: A Systematic Review and Meta-Analysis

    by Masoud Hassanzadeh Makoui, Shiva Fekri, Zahra Jafari, Reza Hassanzadeh Makoui, Negar Ansari, Shima Shokrzadeh

    Background: Pancreatic cancer (PC) is a highly aggressive malignancy known for its late diagnosis and poor prognosis, making it one of the leading causes of cancer-related mortality worldwide. Identifying the molecular alterations involved in the prognosis of PC is essential. One such factor is HER3 overexpression, which can contribute to cancer cell survival, metastasis, and reduced overall survival (OS) in patients by activating cellular signaling pathways. This meta-analysis investigates the rate of HER3 overexpression in pancreatic cancer patients and examines how this overexpression affects their survival rates. Materials and Methods: A comprehensive search was conducted across PubMed, Embase, Web of Science, and Scopus databases up to August 2024. Studies evaluating the association between HER3 overexpression and PC were collected following specific inclusion and exclusion criteria. The rate ratio (RR) with 95% confidence intervals (CI) was calculated. Heterogeneity and publication bias were evaluated, and the extent of HER3 overexpression in patients with PC was analyzed. Also, the studies’ quality was evaluated using the Newcastle-Ottawa Quality Assessment Scale. The research protocol has been registered on PROSPERO under the registration number CRD42024584939. Results: Four studies involving 345 patients with PC were selected for analysis to assess the role of HER3 overexpression on OS. Seven studies involving 536 patients were also included to evaluate the rate of HER3 overexpression in PC patients. Findings indicate that 47.8% of PC patients showed overexpression of HER3 (CI 95%: 34.1-61.9). Additionally, HER3 overexpression was significantly linked to a poorer overall survival rate of patients with PC (OR: 0.605, 95% CI: 0.401-0.913, P= 0.017). Conclusion: In summary, our results reveal that a significant proportion of PC patients show overexpression of HER3, suggesting its potential role as a target for immunotherapy. The findings also highlight the promise of HER3 as a prognostic biomarker in PC.


  • Open Access

    Hypertension, Lifestyle Factors, and Breast Cancer Outcomes: A Decade-Long Retrospective Cohort Study

    by Masoud Hassanzadeh Makoui, Reza Hassanzadeh Makoui, Shiva Fekri, Negar Ansari, Fazel Shokri, Mohammad Mehdi Amiri, Lobat Geranpayeh

    Background & Objective: Breast cancer is the second leading cause of cancer-related mortality in women and is influenced by genetic, environmental, and lifestyle factors. This study aimed to evaluate the prevalence of risk factors in breast cancer patients and their association with disease progression and survival. Materials & Methods: A retrospective ...

  • Open Access

    State of the art in CAR-based therapy: In vivo CAR production as a revolution in cell-based cancer treatment

    by Abdolreza Esmaeilzadeh, Kaveh Hadiloo, Sara Yaghoubi, Masoud Hassanzadeh Makoui, Parsa Mostanadi

    Chimeric antigen receptor (CAR) therapy has successfully treated relapsed/refractory hematological cancers. This strategy can effectively target tumor cells. However, despite positive outcomes in clinical applications, challenges remain to overcome. These hurdles pertain to the production of the drugs, solid tumor resistance, and side effects related to the treatment. Some cases have been missed during the drug preparation due to manufacturing issues, prolonged production times, and high costs. These challenges mainly arise from the in vitro manufacturing process, so reevaluating this process could minimize the number of missed patients. The immune cells are traditionally collected and sent to the laboratory; after several steps, the cells are modified to express the CAR gene before being injected back into the patient’s body. During the in vivo method, the CAR gene is introduced to the immune cells inside the body. This allows for treatment to begin sooner, avoiding potential failures in drug preparation and the associated high costs. In this review, we will elaborate on the production and treatment process using in vivo CAR, examine the benefits and challenges of this approach, and ultimately present the available solutions for incorporating this treatment into clinical practice.


  • Open Access

    Investigating the Co-Expression Rate of HER2 and HER3 Biomarkers in Cancer Patients: A Systematic Review and Meta-Analysis

    by Reza Hassanzadeh Makoui, Shiva Fekri, Negar Ansari, Masoud Hassanzadeh Makoui

    Background: Many types of cancer express the HER2/HER3 heterodimer, which is a crucial oncogenic unit. Research has shown that when these two biomarkers are expressed together, it correlates with higher tumor aggressiveness and lower overall survival rate. Therefore, many therapies have been developed to target both biomarkers simultaneously. This study aims to collect data on the co-expression levels of these biomarkers across different types of cancers. Methods: A comprehensive search was conducted across PubMed, Scopus, Embase, and Web of Science databases to identify relevant studies. The event rates and their corresponding 95% confidence intervals were calculated. Heterogeneity, subgroup, and meta-regression analyses were conducted based on patients’ residency region, age, and gender. The protocol of this study was registered in PROSPERO under ID: CRD42024504256. Results: We have detected 60 studies that met all of the inclusion criteria for our research. Out of these, we have focused on a total of 19 studies (with 6,079 participants) related to breast cancer, 9 studies (with 829 participants) related to lung cancer, 6 studies (with 1423 participants) related to gastric cancer, and 4 studies (with 802 participants) related to colorectal cancer for conducting our meta-analysis. According to our results, the co-expression rate of HER2 and HER3 in breast cancer patients is 18.5% (95%CI 11.7–27.9), in colorectal cancer patients is 17.1% (95%CI 2.4–63.4), in gastric cancer patients is 11.3% (95%CI 4.2–17.2), and in lung cancer patients is 12.7% (95%CI 5.2–22.8). The co-expression of HER2 and HER3 in lung cancer has a significant association with patients’ gender (P=0.038). Conclusion: The study found that HER2 and HER3 biomarkers, which are targets for different therapies, are co-expressed in various types of cancer.


  • Open Access

    Correlation between the existence of serum autoantibodies and the risk of endometriosis: A systematic review and meta-analysis

    by Shiva Fekri, Reza Hassanzadeh Makoui, Negar Ansari, Masoud Hassanzadeh Makoui

    Correlation between the existence of serum autoantibodies and the risk of endometriosis: A systematic review and meta-analysis - Turkish Journal of Obstetrics and Gynecology